Therapies which target the alternative pathways involved in ER+ breast cancer pathology have also been developed; these are increasingly relevant targets for ER+ breast cancer therapeutics due to de novo and acquired resistance of ER+ breast cancer to traditional targeted endocrine therapies. This evidence concerns the gene ESR1 and breast cancer.